Menu ×


Oligonucleotide API Market Analysis by Product type {Reagents & Consumables, Equipment and Synthesized (DNA Oligonucleotides, RNA Oligonucleotides, and Others)}; by Marketing Status (Marketed, and Clinical Trials); and by End User (Pharmaceutical Companies and Biotechnology Companies) – Global Supply & Demand Analysis & Opportunity Outlook 2022-2031

  • Text Size:

Inflation And Looming Recession to Haunt Businesses:

In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.

Request Insights

Purchasing power in the couPurchasing power in the country is expected to fell nearly by 2.5%. On the other hand, European countries to see the worst coming in the form of energy crisis especially in upcoming winters!! Right after COVID-19, inflation has started gripping the economies across the globe. Higher than anticipated inflation, especially in western world had raised concerns for national banks and financial institutions to control the economic loss and safeguard the interest of the businesses. Increased interest rates, strong USD inflated oil prices, looming prices for gas and energy resources due to Ukraine-Russia conflict, China economic slowdown (~4% in 2022) disrupting the production and global supply chain and other factors would impact each industry negatively.                                                         Request Insights

Read More


  • March 28, 2022: Ionis Pharmaceuticals, Inc. in collaboration with Biogen Inc., has announced the results of the investigation of the use of antisense oligonucleotide (ASO) for people with C9orf72-associated amyotrophic lateral sclerosis (ALS).
  • June 15, 2020: Jazz Pharmaceuticals plc has announced that its Zepzelca (Lurbinectedin) has been approved by the U.S. Food and Drug Administration(FDA), for treating adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.

Global Oligonucleotide API Market Size, Forecast, and Trend Highlights Over 2022 - 2031


The global oligonucleotide API market is estimated to garner a revenue of USD 5 Billion by the end of 2031 by growing at a CAGR of ~10% over the forecast period, i.e., 2022 – 2031. Further, the market generated revenue of USD 2 Billion in the year 2021. The growth of the market can be primarily attributed to the rise in laboratory and research institute experiments worldwide. As per the data by the World Bank, as of 2018, there were 1597 researchers per 1,000,000 people involved in research and development activities, an increase from 1412 researchers per million in 2015.


Get more information on this report: Request Sample PDF

The oligonucleotide is a new type of therapeutic molecule ideal for treating a variety of diseases. Oligonucleotide base pairs with DNA or RNA to form a structure. In PCR (polymerase chain reaction), oligonucleotides are commonly used as primers. In addition, funding in life science activities, innovation product launches, and drug discovery, along with investments in high-profile big science projects are expected to drive demand for oligonucleotide API during the forecast period. According to estimates, governments around the world and international organizations are expected to invest a total of more than USD 170 billion on large-scale science projects between 2022 and 2025.

Global Oligonucleotide API Market: Growth Drivers and Challenges

Growth Drivers

  • Globally Rising Prevalence of Cancer and Neurodegenerative Diseases- Based on data from the National Cancer Institute, as of 2020, there were 1,806,590 new cancer diagnoses in the United States and 606,520 cancer deaths. The rising number of cancer cases is propelling the demand for advanced testing procedures. Moreover, the treatment of neurodegenerative diseases requires a personalized approach as well. In terms of neurodegenerative conditions, Alzheimer's disease is one of the most common. There are several limitations associated with conventional medicine in this area, so oligonucleotide APIs are being studied extensively. This factor is expected to expand the global oligonucleotide API market size during the forecast period. 

  • Growth In Percentage of API Manufacturing Facilities in Emerging Countries- According to the US Food & Drug Administration, there are more than 28% of API manufacturing facilities based in the United States in 2019 catering to the market in the US. 59 % are located in other regions, including 13 percent in China.
  • Increase in Medical Approvals for Oligonucleotides- It was observed that as of 2019, 605 oligonucleotide approval programs were in development, compared with only 200 in 2010. 
  • Growing Expenditures on Healthcare Throughout the World-Global healthcare expenditure accounted for 9.83 billion in 2019 according to data provided by the World Bank, an increase from 9.7 billion in 2018.
  • Rising Per Capita Income Worldwide- The World Bank reported that worldwide annual per capita income increased by 4.8% in 2021, up from 1.5% in 2019


  • High Production Costs Associated With Oligonucleotide 
  • Complex Procedure For Manufacturing
  • Mandatory Good Manufacturing Practice Guidelines And Product Licensing

The global oligonucleotide API market is segmented and analyzed for demand and supply by end user into pharmaceutical companies and biotechnology companies. Among these segments, the pharmaceutical companies segment is anticipated to capture the largest market size in the global oligonucleotide API market. The increasing and versatile use of oligonucleotides in the pharmaceutical industry for treatment of various illnesses is expected to drive segment growth during the forecast period. For instance, a variety of oligonucleotides has become increasingly popular in the pharmaceutical industry, including antisense oligonucleotides, short interfering RNAs, splice-switching oligonucleotides, microRNAs, immunostimulatory oligonucleotides, and aptamers. 

Major Macro-Economic Indicators Impacting the Market Growth


According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Oligonucleotide API Market Regional Synopsis

Regionally, the global oligonucleotide API market is studied into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Amongst these markets, the market in North America is projected to hold the largest market share by the end of 2031. Increasing R&D investments in drug discovery and commercialization of oligonucleotide therapies are expected to drive the regional market during the forecast period. Moreover, increased healthcare spending along with enhanced healthcare facilities are further anticipated to fuel the oligonucleotide API market in the region over the forecast period. A recent report from the Centers for Medicare & Medicaid Services revealed that approximately 19.7% of GDP in the United States was spent on healthcare services in 2020, amounting to USD 4.1 trillion in total.


The global oligonucleotide API market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

Market Segmentation

Our in-depth analysis of the global oligonucleotideAPImarket includes the following segments:

By Product Type

  • Reagents & Consumables
  • Equipment and Synthesized
    • DNA Oligonucleotides
    • RNA Oligonucleotides
    • Others

By Marketing Status

  • Marketed
  • Clinical Trials

By End User

  • Pharmaceutical Companies
  • Biotechnology Companies

Top Featured Companies Dominating the Global Oligonucleotide API Market

  • Ionis Pharmaceuticals, Inc.

    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • Jazz Pharmaceuticals plc 
  • Biogen Inc.
  • Sarepta Therapeutics
  • Alnylam Pharmaceuticals, Inc.
  • Corden Pharma GmbH
  • Dynavax Technologies
  • GE Healthcare Life Sciences
  • Nitto Denko Avecia
  • STA Pharmaceutical Co. Ltd.


Related Reports

Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved